The Precision Peptide Company Inc. PNGAF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,262.75% | 9,762.50% | 2,058.06% | 298.89% | -49.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,262.75% | 9,762.50% | 2,058.06% | 298.89% | -49.50% |
| Cost of Revenue | 2,152.00% | 3,318.18% | -44.90% | -61.54% | -97.01% |
| Gross Profit | 2,365.38% | 13,833.33% | 196.28% | 136.74% | 103.53% |
| SG&A Expenses | 193.11% | 274.47% | 269.86% | 130.47% | 73.45% |
| Depreciation & Amortization | 16,750.00% | 33,200.00% | 11,000.00% | 6,560.00% | -122.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 199.76% | 281.20% | 251.26% | 118.34% | 56.54% |
| Operating Income | -190.67% | -270.71% | -243.62% | -116.17% | -57.99% |
| Income Before Tax | -329.49% | -463.62% | -460.38% | -333.94% | -61.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -329.49% | -463.62% | -460.38% | -333.94% | -61.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -329.49% | -463.62% | -460.38% | -333.94% | -61.19% |
| EBIT | -190.67% | -270.71% | -243.62% | -116.17% | -57.99% |
| EBITDA | -187.03% | -261.77% | -236.90% | -111.12% | -56.52% |
| EPS Basic | -25.71% | -27.68% | -6.97% | 5.63% | 19.25% |
| Normalized Basic EPS | 12.63% | 14.65% | 27.70% | 38.39% | 19.48% |
| EPS Diluted | -25.71% | -27.68% | -6.97% | 5.63% | 19.25% |
| Normalized Diluted EPS | 12.63% | 14.65% | 27.70% | 38.39% | 19.48% |
| Average Basic Shares Outstanding | 180.68% | 280.91% | 363.01% | 265.44% | 140.61% |
| Average Diluted Shares Outstanding | 180.68% | 280.91% | 363.01% | 265.44% | 140.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |